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BACKGROUND: Companion diagnostics (CD) testing aims to stratify the patient 
population. It conditions the choice of best available therapeutic options, limiting 
targeted therapy (TT) to subgroups most likely to benefit and triggers potential cost 
savings. OBjeCtives: To provide a general framework and a list of key methodo-
logical points to be addressed while conducting a model-based economic evaluation 
of CD-TT pairings, especially in oncology. MethODs: Based on a health economic 
literature review and a clinical expert panel with examples drawn from cases of CD 
testing selection biomarker predictive of the response level towards an anti-cancer 
TT. ResUlts: As CD and TT have embedded values, it is important to assess them 
concomittantly within a shared modeling framework. We propose a decision tree to 
model the patient population stratification and to incorporate impacts of analytical 
and clinical validity. The former refers here to the inability of the CD to accurately 
and reliably inform the biomarker resulting in true (false) positive/negative cases, 
whereas the latter relates to the penetrance, i.e. the strength of association between 
the biomarker and clinical phenotypes (treatment effect). Such parameters are crucial 
especially in cases multiple distinct lab-tests (commercial vs. home-brew, technics, 
amount of informations provided regarding the biomarker). Each patient sub-group 
outcomes are required to be modeled (costs and health effects). A Markov state-tran-
sition model either based on treatment pathway and/or disease staging represents 
both adequate approaches to simulate the clinical outcomes, incorporating specific 
efficacy parameters per sub group depending on their biomarker expression levels. 
In instances, time spent until the CD result delivery exceeds a clinical significant 
threshold, testing delay shall be modelled such as all parameters driving loss of oppo-
runity. CONClUsiONs: Beyond reasonable simple binary-type of selection biomarker, 
more complex types of biomarkers and CD technologies (full sequences) has risen 
additional complexity and poses new methodological challenges.
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OBjeCtives: Quantitative patient preferences are increasingly considered for health 
care policy decisions. The objective of this study is to develop a methodology to 
combine patient preferences with clinical evidence in a multi-criteria framework 
that takes into account uncertainty in both preferences and clinical evidence. The 
methodology will be illustrated with a case on antiretroviral treatments. MethODs: 
Treatments under consideration are eight highly active antiretroviral therapies 
(HAART) recommended for treatment-naïve patients by the National Institute of 
Health. The treatments are compared on the probabilities of virologic failure, hyper-
sensitivity reaction, bone damage, and kidney damage; and on the treatability of 
bone/kidney damage. Preferences from 147 patients were elicited with a discrete 
choice method in an earlier study. Preferences were assumed to be distributed with 
a multivariate normal distribution. Treatment performances as identified from clini-
cal trials were assumed to be distributed with beta distributions. The probability 
distributions around preferences and clinical performances were combined with a 
Monte Carlo simulation method to estimate the joint probability distribution around 
each treatment’s patient-weighted utility. ResUlts: The three treatments with the 
highest mean patient-weighted utility were dolutegravir+abacavir/lamivudine (-0.4, 
95% CI: -1.3 to 0.5), raltegravir+tenofovir/emtricitabine (-0.5, 95% CI: -1.6 to 0.7) and 
darunavir/ritonavir+tenofovir/emtricitabine (-0.6, 95% CI: -2.0 to 0.8). There was con-
siderable overlap between the probability distributions of patient-weighed utilities 
(probability of first rank reversal: 49%; probability of any rank reversal: > 99%). When 
ignoring uncertainty around patient preferences, the probability of a first rank rever-
sal dropped to 12%, and that of any rank reversal dropped to 88%. CONClUsiONs: 
A probabilistic multi-criteria methodology was developed that explicitly combines 
patient preferences and clinical evidence. The individual or joint impact of uncer-
tainty in these on the treatments’ patient-weighted utilities is assessed. Although 
limited by the small number of attributes, the illustrative case suggests the choice 
of HAART is highly sensitive to patient preferences.
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OBjeCtives: Cross-sectional studies showed that, for modelling health-related 
quality of life (HRQoL), beta regression is superior in terms of fit and predictive accu-
racy to other commonly used methods based on normality distribution assumption. 
Although, longitudinal HRQoL measurements are widely used in clinical trials, not 
much is known about beta regression suitability in this context. This is mainly due 
to software unavailability with classical estimation methods. This study proposes 
to model the longitudinal HRQoL outcome using a mixed beta regression estimated 
by Bayesian Markov chain Monte Carlo (MCMC) methods implemented in WinBUGS. 
Compared to the classical approach, not only the Bayesian estimation is consider-
ably easier to implement but has other advantages; for example, the possibility of 
including informative priors, enabling analysts to incorporate multiple sources of 
evidence in a single model. MethODs: We used a 16-year longitudinal follow-up 
for modelling the relationship between SF-6D HRQoL and variables age, gender and 
mortality risk by means of a mixed beta regression. Besides modelling the mean 
tant to identify patients who are most likely to benefit. Doing so using clini-
cal trials is prohibitively expensive; thus a mathematical modeling approach is 
required. MethODs: We developed a framework for stratified cost-effectiveness 
analysis using individual-based discrete-event simulations, consisting of a natu-
ral history component that captures mutation distribution, correlations between 
mutation and other risk factors (e.g. family history), and cancer incidence, progres-
sion and mortality, and a health care process component that captures interac-
tions between the patients and the health care system, through genetic testing, 
screening, diagnosis and treatment, and their costs. The genetic screening strat-
egy consists of 3 steps: a benefit- risk assessment step, in which patients are 
assessed for risk of carrying mutations and potential benefits from genetic testing, 
a genetic testing step, in which qualified patients within an optimal risk bracket 
are given the appropriate tests and an intervention step, in which patients are 
given care based on the results from the genetic tests. ResUlts: We use the fol-
lowing approach to explore and identify optimal strategies for 3 genetic screening 
applications: Dinh et al. demonstrated that primary screening for Lynch syndrome 
in patients at least 25 years old and with a risk of at least 5% was cost effective. 
Folse et al. showed that single-nucleotide polymorphism (SNP) screening for breast 
cancer risk for recommending patients to MRI screening was most cost-effective 
in women age 40 with a lifetime risk of 16 to 28%. Green et al showed that the 
same genetic test for recommending patients to chemoprevention was most cost-
effective for women age 50-59 with a 5-year risk of 1.2-1.66%. CONClUsiONs: As 
more genetic tests becomes available, this method can be used to identify screen-
ing strategies that maximize cost-effectiveness.
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OBjeCtives: To develop a flexible and computationally efficient discrete event 
simulation (DES) model which could be employed in a cost-effectiveness analysis 
comparing the use of PET-CT scans versus current diagnostic procedures for Conn’s 
disease in hypertensive patients. MethODs: Visual Basic was used for the model 
simulation with Microsoft Excel constituting the front-end software. In order to 
ensure a high level of flexibility, individual patients could be assigned a number 
of personal traits and the clinical, cost and utility inputs were easily adjustable. 
Individual diagnostic procedures were programmed in separate modules with the 
aim of simplifying potential modifications to the diagnostic pathway. ResUlts: 
A DES was constructed to evaluate the cost-effectiveness of new treatments based 
on the experience of patients assigned to intervention and comparator arms. 
Patients were considered individually in each arm, using the same background 
mortality. Time, gender and event dependent risk equations enabled efficient model-
ling of endogenous heterogeneity of the population. Continuous time accounting 
allowed for the modelling of competing adverse events and provided a realistic 
representation of patients’ experience. Preliminary results indicate that the 
use of PET-CT scans for the screening of Conn’s syndrome could be cost-effec-
tive. CONClUsiONs: The newly developed model is the first formal attempt to 
evaluate the cost-effectiveness of this alternative screening technique for hyper-
tensive patients who are suspected of suffering from Conn’s disease. The model will 
be further developed to include probabilistic sensitivity analysis and bootstrapping 
in order to evaluate the robustness of the potential results. Evolutionary algorithms 
will be incorporated to define the most optimal solution from the continuous spec-
trum of potential screening strategies. As the model will utilise actual patient level 
data, it could be used by the decision maker to determine the most cost-effective 
diagnostic strategy.
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OBjeCtives: Patients’ experience of OIC may be unstable, with periods of con-
stipation and non-constipation, an observation supported by physician reports. 
There is, however, a lack of quantitative evidence of this experience. Such evidence 
would be valuable to inform development of economic models for OIC treatments. 
The objective of this abstract is to fill this gap utilizing data from two pivotal 
Naloxegol studies, KODIAC 4 and 5, which demonstrated significant improvements 
in SBM frequency response compared to placebo over 12 weeks. MethODs: 892 
non-cancer pain patients with OIC were randomized to Naloxegol 25 mg or pla-
cebo in two pivotal studies. A 4-week rolling determination of OIC and non-OIC 
status at weeks 4 through 12 was used in time-to-event analyses. Patients were 
considered OIC if they reported < 3 SBMs for > = 2 out of the 4 weeks and non-OIC 
if reported > = 3 SBMs for > = 3 out of 4 weeks. Those with non-OIC status at week 
4 were selected as the baseline and first observed OIC status was considered an 
event. Parametric analyses with Exponential, Weibull, Gompertz, Log-normal, Log-
logistic, and Generalized Gamma distributions were conducted. ResUlts: Based 
on the parametric time-to-event analysis results, the Log-normal distribution was 
selected as the best fit and provided plausible long term projections. Naloxegol had 
a noticeable separation for extending the time to first OIC event when compared 
to placebo over the projected long-term follow-up. CONClUsiONs: This research 
demonstrates that the natural fluctuation between OIC and non-OIC is substantial 
and requires integration into an economic model. Even in the absence of treat-
ment, a substantial proportion of patients become non-OIC, and a significant 
proportion of these remain in non-OIC subsequently. Nevertheless, a treatment 
effect for Naloxegol was observed over and above this ‘background’ placebo vari-
ation in the experience of OIC.
